
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SNVL-31
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Immorta Bio Shows Preclinical Activity of SenoVax in CTE Model
Details : SenoVax (SNVL-31) is the first-in-class senolytic immunotherapy that utilizes patient-specific to train the immune system to clear senescent cells, for chronic traumatic encephalopathy.
Product Name : SenoVax
Product Type : Vaccine
Upfront Cash : Inapplicable
September 24, 2025
Lead Product(s) : SNVL-31
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
